Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00213993 · ClinicalTrials.gov registry record · Phase 2
Topical Antiperspirant for Hand-Foot Syndrome
A Phase 2 study of Palmar-plantar Erythrodysesthesia, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00213993 is a Phase 2 study of Palmar-plantar Erythrodysesthesia that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00213993, a Phase 2 study of Palmar-plantar Erythrodysesthesia, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.
Conditions Studied
Interventions
- DRUG antiperspirant
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00213993
The ClinicalTrials.gov registry entry for NCT00213993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Palmar-plantar Erythrodysesthesia appearing as the primary indexed condition, and to 1 intervention - of which antiperspirant is the first listed.
NCT00213993 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00213993 about?
NCT00213993 is a clinical study titled "Topical Antiperspirant for Hand-Foot Syndrome". The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in swea...
What is the current status of trial NCT00213993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2005-05. Estimated completion is 2007-01.
What conditions does trial NCT00213993 study?
This clinical trial studies the following conditions: Palmar-plantar Erythrodysesthesia.
What interventions are being tested in trial NCT00213993?
The interventions under investigation include: antiperspirant (DRUG).
Who is sponsoring clinical trial NCT00213993?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00213993 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Palmar-plantar Erythrodysesthesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.